Redhawk Wealth Advisors Inc. Sells 895 Shares of Pfizer Inc. (NYSE:PFE)

Redhawk Wealth Advisors Inc. lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,971 shares of the biopharmaceutical company’s stock after selling 895 shares during the quarter. Redhawk Wealth Advisors Inc.’s holdings in Pfizer were worth $211,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Roble Belko & Company Inc lifted its position in Pfizer by 49.7% during the fourth quarter. Roble Belko & Company Inc now owns 5,801 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 1,926 shares during the last quarter. Advisors Management Group Inc. ADV increased its position in shares of Pfizer by 1.4% during the fourth quarter. Advisors Management Group Inc. ADV now owns 192,185 shares of the biopharmaceutical company’s stock worth $5,099,000 after purchasing an additional 2,706 shares in the last quarter. ARS Wealth Advisors Group LLC lifted its holdings in shares of Pfizer by 4.9% during the 4th quarter. ARS Wealth Advisors Group LLC now owns 24,967 shares of the biopharmaceutical company’s stock valued at $662,000 after purchasing an additional 1,176 shares during the last quarter. Burney Co. boosted its position in shares of Pfizer by 262.8% in the 4th quarter. Burney Co. now owns 143,731 shares of the biopharmaceutical company’s stock worth $3,813,000 after purchasing an additional 104,112 shares in the last quarter. Finally, Apella Capital LLC grew its stake in Pfizer by 16.7% during the 4th quarter. Apella Capital LLC now owns 21,228 shares of the biopharmaceutical company’s stock worth $563,000 after buying an additional 3,035 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PFE. Citigroup started coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target for the company. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Wolfe Research initiated coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. Finally, Guggenheim reduced their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Stock Up 1.1 %

Shares of PFE stock opened at $26.51 on Friday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a market cap of $150.20 billion, a P/E ratio of 35.82, a P/E/G ratio of 0.64 and a beta of 0.64. The stock has a 50 day moving average of $26.11 and a 200 day moving average of $28.01. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.17) EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.49%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.